Christopher Adams, MD
Interventional Cardiology · Paducah, KYNPI 1447411459
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,307 of the $3,507 with a category attached, or 65.8%. 19 manufacturers reported payments, led by Abbott at 42.4% of the total. Reporting peaked in 2024 at $1,637 and has fallen 78.1% since, to $358 in 2025. That places this record below the midpoint for interventional cardiology clinicians in KY, where the typical reported total is $7,951.
Across 78 payments — averaging $44.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Inari Medical, Inc.$802
- Abiomed$203
- Cardiovascular Systems Inc.$125
- Angiodynamics, Inc.$123
- Amgen$122
- plus $647 from 13 others
Across 16 payments — averaging $2800.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$45K
What the payments were for
- Consulting fees$251%
- Travel & lodging$1,17534%
- Food & beverage$2,30766%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $1,486 |
| Inari Medical, Inc. | 10 | $802 |
| Abiomed | 9 | $203 |
| Cardiovascular Systems Inc. | 2 | $125 |
| Angiodynamics, Inc. | 3 | $123 |
| Amgen | 8 | $122 |
| Edwards Lifesciences | 3 | $104 |
| Heartflow, Inc. | 2 | $86 |
| Pfizer | 4 | $74 |
| Johnson & Johnson | 3 | $70 |
| Medtronic(2 entities) | 4 | $68 |
| Boston Scientific | 4 | $63 |
| Novartis | 3 | $51 |
| Novo Nordisk | 1 | $27 |
| Getinge USA Sales, LLC | 1 | $27 |
| Cook Medical LLC | 1 | $25 |
| ZOLL Circulation Inc | 1 | $19 |
| Shockwave Medical, Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,507 in reported general payments places this provider in the 25th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $99,918 |
| EntrestoSacubitril/Valsartan | 49 | $56,230 |
| XareltoRivaroxaban | 32 | $26,573 |
| Repatha SureclickEvolocumab | 36 | $23,791 |
| Prasugrel Hcl | 28 | $4,614 |
| Ranolazine ErRanolazine | 22 | $1,993 |
| Metoprolol Succinate | 93 | $1,705 |
| Atorvastatin Calcium | 92 | $1,170 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 35 | $450 |
| Carvedilol | 59 | $408 |
| Furosemide | 81 | $406 |
| Lisinopril | 74 | $361 |
| Cilostazol | 20 | $359 |
| ClopidogrelClopidogrel Bisulfate | 46 | $354 |
| Nitroglycerin | 22 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $99,918117 claims |
| NovartisEntresto | $51 | $56,23049 claims |
| Johnson & JohnsonXarelto | $70 | $26,57332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Paducah
- James FordPaducah$67K
- Shankho GanguliPaducah$56K
- Martin RainsPaducah$45K
- Timothy McDermottPaducah$17K
- Michael FaulknerPaducah$13K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.